Phospho-ESR1 (S106) Antibody

What is Phospho-ESR1 (S106) and why is it significant in research?

Phospho-ESR1 (S106) refers to the Estrogen Receptor alpha (ERα) protein specifically phosphorylated at serine 106 within its transcription activation function 1 (AF-1) domain. This phosphorylation is significant because it can stimulate ERα activity in a ligand-independent manner, meaning the receptor can become activated without estrogen binding. This post-translational modification has critical implications for understanding estrogen signaling dynamics in both normal physiology and disease states, particularly in breast cancer where aberrant ERα activation contributes to pathogenesis and treatment resistance .

Phosphorylation at S106, along with other sites like S104 and S118, represents a key mechanism through which growth factor signaling pathways can cross-talk with estrogen receptor signaling. Research has demonstrated that S106 phosphorylation is mediated by extracellular signal-regulated kinases 1 and 2 (Erk1/2) mitogen-activated protein kinase (MAPK) both in laboratory settings (in vitro) and in living cells (in vivo) . The ability to specifically detect and quantify this modification provides researchers with a powerful tool to investigate the complex regulation of estrogen receptor function.

How does the Phospho-ESR1 (S106) antibody differ from other ESR1 antibodies?

The Phospho-ESR1 (S106) antibody is fundamentally different from standard ESR1 antibodies in its exquisite specificity for the phosphorylated form of the receptor at a single amino acid position. While conventional ESR1 antibodies recognize the receptor regardless of its phosphorylation status, Phospho-ESR1 (S106) antibodies only bind when serine 106 is phosphorylated . This specificity is achieved through careful immunogen design and affinity purification.

The antibodies are typically raised against synthetic phosphopeptides corresponding to the region surrounding serine 106 of human Estrogen Receptor alpha . The specificity of these antibodies can be verified through peptide competition experiments, where pre-incubation with phosphorylated peptides containing S106 blocks antibody binding, confirming that the antibody truly recognizes the phosphorylated epitope rather than merely the surrounding sequence . This specificity makes these antibodies invaluable for studying the dynamics and regulation of ESR1 phosphorylation events in various experimental contexts.

Which experimental techniques are compatible with Phospho-ESR1 (S106) antibodies?

Phospho-ESR1 (S106) antibodies are versatile research tools compatible with multiple experimental techniques commonly used in molecular and cellular biology research. Based on product specifications, these antibodies can be effectively used for Western blotting (WB), immunohistochemistry on paraffin-embedded samples (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF) .

For Western blotting applications, typically a dilution range of 1:500-1:2000 is recommended, though optimal conditions should be determined empirically for each experimental system. For immunofluorescence and immunocytochemistry applications, a dilution range of 1:100-1:200 is generally suggested . When properly optimized, these techniques allow researchers to detect and localize S106-phosphorylated ESR1 in cell lysates, tissue sections, and cultured cells, providing valuable information about the phosphorylation status of the receptor under various experimental conditions and treatments.

How should experiments be designed to effectively study ESR1 phosphorylation at S106?

Designing experiments to study ESR1 phosphorylation at S106 requires careful consideration of multiple factors to ensure accurate and interpretable results. A comprehensive experimental design should include appropriate cellular models, stimulation conditions, inhibition studies, and suitable controls. Cell lines with endogenous ESR1 expression (such as MCF-7 breast cancer cells) or cells transfected with wild-type and mutant ESR1 constructs are commonly used as experimental systems .

To study the dynamics of S106 phosphorylation, researchers should consider including the following experimental conditions:

• Ligand stimulation: Treatment with estradiol (E2, typically 10 nM), 4-hydroxytamoxifen (OHT, 100 nM), or ICI182,780 (ICI, 100 nM) for 30 minutes prior to cell harvesting .

• MAPK pathway activation: Addition of phorbol 12-myristate 13-acetate (PMA, 100 nM) for 15 minutes before harvesting to activate the MAPK pathway .

• MAPK pathway inhibition: Pre-treatment with U0126 (10 μM) for 60 minutes to inhibit MEK1/2, the upstream activator of Erk1/2 MAPK .

• Genetic manipulation: Expression of constitutively active or dominant-negative forms of Ras or Raf to modulate MAPK pathway activity .

Including controls such as phosphorylation-deficient mutants (S106A) and phosphomimetic mutants (S106E) is crucial for validating antibody specificity and understanding the functional consequences of S106 phosphorylation.

What are the optimal conditions for using Phospho-ESR1 (S106) antibody in Western blotting?

For optimal Western blotting results with Phospho-ESR1 (S106) antibody, researchers should follow a carefully optimized protocol that preserves phosphorylation status while minimizing background and maximizing specific signal. Begin with proper sample preparation by harvesting cells directly into Laemmli buffer containing phosphatase inhibitors to prevent dephosphorylation artifacts . This immediate denaturation helps preserve the phosphorylation state of ESR1.

The recommended protocol includes:

• Sample preparation: Lyse cells directly in buffer containing phosphatase inhibitors and protease inhibitors.

• Gel electrophoresis: Separate proteins on 8-10% SDS-PAGE gels for optimal resolution of ESR1 (66 kDa).

• Transfer: Use PVDF membrane for better protein retention and signal quality.

• Blocking: Block with 5% BSA in TBST rather than milk, as milk contains phosphatases that may reduce signal.

• Primary antibody: Incubate with Phospho-ESR1 (S106) antibody at 1:500-1:2000 dilution overnight at 4°C .

• Validation: Include phosphopeptide competition controls to confirm specificity .

• Loading control: Probe for total ESR1 on the same or parallel blots to normalize phospho-signal to total protein levels.

• Quantification: Perform densitometry to quantify the phospho-ESR1 signal relative to total ESR1 .

For optimization, a titration of antibody concentrations is recommended to determine the optimal signal-to-noise ratio for each experimental system.

How can Phospho-ESR1 (S106) antibody specificity be validated in research applications?

Rigorous validation of Phospho-ESR1 (S106) antibody specificity is crucial for ensuring reliable and interpretable research results. Multiple complementary approaches should be employed to confirm that the antibody specifically recognizes ESR1 phosphorylated at S106 and not other phosphorylated residues or proteins.

Key validation strategies include:

• Peptide competition assays: Pre-incubating the antibody with phosphorylated peptides containing S106 should abolish signal detection, while non-phosphorylated peptides should have minimal effect. Competition experiments have demonstrated that antibody binding is specifically blocked by phosphorylated S106 peptides (PS106) and doubly phosphorylated S104/S106 peptides (PS104/6) .

• Mutational analysis: Using cells expressing ESR1 with serine-to-alanine mutations at S106 (S106A) should show abolished or significantly reduced antibody binding. Studies have confirmed that S106A mutants are not detected by phospho-S106 specific antibodies, validating their specificity .

• Phosphatase treatment: Treating samples with lambda phosphatase prior to analysis should eliminate antibody signal if it truly recognizes a phosphorylated epitope.

• Stimulus-response correlations: Signal intensity should increase with treatments known to enhance S106 phosphorylation (e.g., PMA, E2) and decrease with MAPK pathway inhibitors (e.g., U0126) .

• Cross-reactivity assessment: Testing the antibody against phosphomimetic mutants (S106E) and other phosphorylation site mutants (S104A, S118A) to assess potential cross-reactivity with similar epitopes .

What is the functional significance of ESR1 phosphorylation at serine 106?

ESR1 phosphorylation at serine 106 plays a crucial role in modulating receptor activity and transcriptional output. Research has demonstrated that S106 phosphorylation stimulates ESR1 activity in a ligand-independent manner, allowing the receptor to activate gene expression even in the absence of estrogen binding . This mechanism represents an important node of cross-talk between growth factor signaling pathways and estrogen receptor signaling.

Functionally, S106 phosphorylation appears particularly important for the agonist activity of the selective estrogen receptor modulator (SERM) 4-hydroxytamoxifen (OHT). Experiments have shown that while S118 is important for the stimulation of ESR1 activity by OHT, S104 and S106 are also required for its full agonist activity . This finding has significant implications for understanding the mechanism of action of tamoxifen and potential resistance mechanisms in breast cancer treatment.

Interestingly, substitution of S106 with acidic amino acids (mimicking constitutive phosphorylation) stimulates ESR1 activity to a greater extent than equivalent substitutions at S118, suggesting that phosphorylation at S106 may be particularly important for ESR1 transcriptional activity . This suggests that S106 phosphorylation may be a critical regulatory event in determining receptor activity in various physiological and pathological contexts.

How does S106 phosphorylation interact with other ESR1 post-translational modifications?

S106 phosphorylation exists within a complex network of post-translational modifications (PTMs) that collectively determine ESR1 function. Research indicates significant crosstalk between phosphorylation events at S104, S106, and S118, suggesting a sophisticated regulatory mechanism controlling ESR1 activity .

Experimental evidence demonstrates that the phosphorylation status of one serine residue influences the phosphorylation of others. For instance, S104 phosphorylation is influenced by the status of S106 and S118, suggesting that phosphorylation at S106 and S118 may be important for subsequent phosphorylation of S104. Similarly, S106 phosphorylation is reduced in S118A mutants, indicating that S118 plays a role in promoting S106 phosphorylation . This interdependence creates a complex regulatory network where sequential or combinatorial phosphorylation events determine the ultimate functional outcome.

Beyond the relationship with other phosphorylation sites, ESR1 undergoes numerous other post-translational modifications, including glycosylation, ubiquitination, methylation, and palmitoylation . These modifications collectively regulate ESR1 stability, localization, and activity. For instance, glycosylation with N-acetylglucosamine occurs in a presumably O-linked manner, while ubiquitination regulated by factors like LATS1 via DCAF1 leads to ESR1 proteasomal degradation . The interplay between S106 phosphorylation and these other modifications remains an important area for further investigation.

Which kinases are responsible for phosphorylating ESR1 at S106?

The phosphorylation of ESR1 at S106 is primarily mediated by extracellular signal-regulated kinases 1 and 2 (Erk1/2) of the mitogen-activated protein kinase (MAPK) pathway. Both in vitro experiments and studies in living cells have confirmed that MAPK can directly phosphorylate S106 . This phosphorylation can be stimulated by activators of the MAPK pathway such as phorbol 12-myristate 13-acetate (PMA) and can be inhibited by the MEK1/2 inhibitor U0126 or expression of kinase-dead Raf1, confirming the involvement of the MAPK signaling cascade .

In addition to MAPK, other kinases have been implicated in S106 phosphorylation under specific contexts. For instance, Cyclin-dependent kinase 2 (Cdk2) has been reported to phosphorylate S104 and/or S106 . Glycogen synthase kinase 3 (GSK3) has also been suggested as a potential kinase for these sites . The involvement of multiple kinases suggests that S106 phosphorylation may serve as an integration point for various signaling pathways that converge on ESR1 to regulate its activity.

The specific kinase responsible for S106 phosphorylation may depend on the cellular context, the presence of other stimuli, and the phosphorylation status of neighboring residues, highlighting the complexity of ESR1 regulation through post-translational modifications.

How is Phospho-ESR1 (S106) involved in tamoxifen resistance in breast cancer?

Research has demonstrated that S106 phosphorylation, along with phosphorylation at S104 and S118, is required for the agonist activity of 4-hydroxytamoxifen (OHT), the active metabolite of tamoxifen . This suggests that increased phosphorylation at these sites could enhance the agonist properties of tamoxifen, potentially converting it from an antagonist to a partial agonist in breast cancer cells, thus compromising its therapeutic efficacy.

The MAPK-mediated hyperphosphorylation of ESR1 at S104, S106, and S118 appears to be particularly relevant to tamoxifen resistance mechanisms . In breast cancer cells with elevated MAPK activity, perhaps due to overexpression or hyperactivation of upstream growth factor receptors like EGFR or HER2, increased phosphorylation at these sites could promote ligand-independent activation of ESR1 and reduce dependence on estrogen, thereby circumventing the inhibitory effects of tamoxifen. This mechanism provides a molecular explanation for the clinical observation that patients with tumors exhibiting high MAPK activity often respond poorly to tamoxifen therapy.

What are the analytical challenges in quantifying S106 phosphorylation in clinical samples?

Quantifying S106 phosphorylation in clinical samples presents several significant analytical challenges that researchers must address to obtain reliable and clinically meaningful data. These challenges span sample collection, processing, analysis, and interpretation phases.

Key analytical challenges include:

• Phosphorylation lability: Phosphorylation is an extremely labile post-translational modification that can be rapidly lost during sample collection and processing due to endogenous phosphatase activity. Clinical samples often experience variable ischemic times before fixation or freezing, potentially introducing significant pre-analytical variability in phosphorylation levels.

• Heterogeneity of clinical samples: Tumor tissue contains a mixture of cancer cells, stromal cells, and immune cells, complicating the interpretation of bulk phosphorylation measurements. Techniques that provide cellular resolution, such as immunohistochemistry, may be preferable but introduce other quantification challenges.

• Antibody specificity in complex matrices: While antibodies may demonstrate excellent specificity in controlled research settings with cell lines, clinical samples present a more complex matrix with potential for cross-reactivity or interference.

• Normalization strategy: Determining the appropriate normalization approach is critical – whether to normalize phospho-S106 signals to total ESR1 levels, to housekeeping proteins, or to use absolute quantification approaches.

• Threshold determination: Establishing clinically meaningful thresholds for "high" versus "low" phosphorylation levels requires careful correlation with biological outcomes and extensive validation across diverse patient cohorts.

To address these challenges, researchers typically employ a combination of approaches, including immediate sample preservation, phosphatase inhibitor use, careful validation with appropriate controls, and correlation of quantitative measurements with clinical outcomes.

How can phosphorylation status at S106 be integrated with other ESR1 biomarkers in breast cancer research?

Integrating S106 phosphorylation data with other ESR1 biomarkers represents an advanced research application that can provide a more comprehensive understanding of ESR1 regulation and function in breast cancer. This multi-parameter approach acknowledges the complexity of ESR1 signaling and may offer improved predictive and prognostic information compared to single biomarkers.

Strategies for integration include:

What are common technical issues when working with Phospho-ESR1 (S106) antibodies and how can they be resolved?

Working with phospho-specific antibodies like those targeting ESR1 S106 presents several technical challenges that can impact experimental success. Understanding these issues and implementing appropriate solutions is essential for generating reliable and reproducible data.

Common technical issues and solutions include:

• Low or absent signal

  • Cause: Dephosphorylation during sample preparation, insufficient antibody concentration, or low target abundance

  • Solution: Add phosphatase inhibitors to all buffers, optimize antibody concentration through titration experiments, enrich for ESR1 by immunoprecipitation before Western blotting, or stimulate cells with MAPK activators like PMA to increase phosphorylation levels

• High background or non-specific bands

  • Cause: Insufficient blocking, cross-reactivity with other phosphorylated proteins, or excessive antibody concentration

  • Solution: Optimize blocking conditions (using BSA instead of milk for phospho-epitopes), increase washing stringency, titrate antibody to find optimal concentration, and validate specificity using peptide competition assays

• Variable results between experiments

  • Cause: Inconsistent sample preparation, variable phosphorylation status, or differences in cell culture conditions

  • Solution: Standardize cell culture and treatment protocols, include positive controls (PMA-treated samples) , and normalize phospho-signal to total ESR1 levels

• Poor reproducibility in tissue samples

  • Cause: Variable tissue fixation, antigen retrieval issues, or endogenous phosphatase activity

  • Solution: Standardize fixation time, optimize antigen retrieval protocols, and ensure tissues are processed quickly to preserve phosphorylation status

• Peptide competition inconsistencies

  • Cause: Incorrect peptide concentration, non-specific binding, or antibody batch variation

  • Solution: Titrate blocking peptide concentration, ensure peptides contain the exact epitope sequence, and verify that phosphorylated peptides block signal while non-phosphorylated versions do not

How should researchers interpret changes in S106 phosphorylation in the context of total ESR1 levels?

Best practices for interpretation include:

• Dual measurement approach: Always measure both phospho-S106 and total ESR1 in the same experiment, ideally on the same membrane by stripping and reprobing or on parallel samples processed identically .

• Normalization strategies: Calculate the ratio of phospho-S106 to total ESR1 to determine the proportion of the receptor that is phosphorylated. This normalized value provides more meaningful biological information than absolute phospho-signal alone.

• Context-dependent interpretation:

  • Increased phospho-S106 with unchanged total ESR1: Suggests enhanced kinase activity or reduced phosphatase activity specifically affecting S106

  • Increased phospho-S106 with increased total ESR1: May indicate elevated phosphorylation rate but requires normalization to determine if the proportion of phosphorylated receptor has changed

  • Decreased phospho-S106 with decreased total ESR1: May simply reflect lower receptor levels rather than reduced phosphorylation rate

• Time-course considerations: Phosphorylation events often occur rapidly and transiently. Interpreting a single time point may miss important dynamic changes. Consider examining multiple time points after stimulation to capture the full phosphorylation profile .

• Complementary approaches: When possible, complement antibody-based detection with other techniques such as mass spectrometry-based phosphoproteomics or radioactive orthophosphate labeling to validate findings using orthogonal methods.

What controls should be included when conducting phosphorylation site-specific experiments?

Rigorous experimental design for phosphorylation site-specific studies requires comprehensive controls to ensure valid and interpretable results. When investigating ESR1 S106 phosphorylation, researchers should include the following essential controls:

Including these comprehensive controls ensures that observed changes in S106 phosphorylation are specific, reliable, and biologically meaningful.